ReportPages
- About STOP AMR
- Blog
- Contact
- Cookie Policy
- Get Involved
- Home
- Legal Disclaimer
- Privacy Policy
- Report an AMR outbreak
- Sitemap
- Tell us your AMR story
- Travel Advice
- What you can do
Posts by category
- Category: Policy
- Category: New studies
- Category: Antimicrobial R&D
News
- Newsletter 8-19 June
- Newsletter 30 May - 7 June
- Summary: The Magistral Phage –A Belgian initiative
- Newsletter 16-29 May
- Webinar on AMR - Addressing the Antibiotic Market Failure, 4 June 2020 at 12:00-13:00 CET
- Newsletter 01-15 May
- Newsletter 25-30 April
- Newsletter 18-24 April
- Newsletter 04-17 April
- Newsletter 28 March - 03 April
- Newsletter 21 - 27 March 2020
- Newsletter 14 - 20 March 2020
- Newsletter 7 - 13 March 2020
- Newsletter 29 February-6 March 2020
- Newsletter 22-28 February 2020
- Newsletter 15-21 February 2020
- Newsletter 8-14 February 2020
- Newsletter 1-7 February 2020
- Newsletter 25-31 January 2020
- Newsletter 18–24 January 2020
- Newsletter 11-17 January 2020
- Newsletter 1-10 January 2020
- Newsletter 14-20 December 2019
- Newsletter 7-13 December 2019
- Special Addition Newsletter November 2019
- Newsletter 16-22 November 2019
- Newsletter 9-15 November 2019
- Newsletter 2-8 November 2019
- Newsletter 28-31 October 2019
Testimonials
FAQs
- How can I stay safe while travelling?
- What is antimicrobial resistance (AMR) and why is it an urgent threat to global health?
- What are the main causes of antimicrobial resistance?
- How does AMR develop and how is it disseminated?
- What does “inappropriate use of antibiotics” mean?
- How many people die every year because of AMR?
- What is the social and economic impact of AMR?
- What are antimicrobial agents and what are they used for?
- What is the difference between antibiotics and other antimicrobial agents?
- Can the same bacteria be resistant to several antibiotics?
- When was the first case of resistance to antibiotics registered?
- Which common illnesses are often wrongly treated with antibiotics?
- What should I do with the unused/expired antibiotics that I have at home?
- If we do not take adequate action, what will happen in the future?
- How do we overcome the problem of AMR at the community level?
- Could taxes on antibiotic use in human and animal health be a solution?
- What is the role of economic investment in Research & Development in AMR?
- Is it true that if AMR is not properly addressed it could cost the global economy up to USD 100 trillion by 2050?
- Does antibiotic use in farm animals contribute to the spread of resistant bacteria?
- What are the main reasons for antibiotics use in food-producing animals?
- Are there alternatives to antibiotics in husbandry?
- How can improved sanitation in husbandry lead to a decline antibiotics usage?
- Does the food we buy in the supermarkets contain antibiotic-resistant bacteria?
- What is the withdrawal time for antimicrobials?
- What can farmers do to help tackle AMR?
- How does antibiotic use in animals affect humans?
- Are the antimicrobials used in animals identical to those used in treating infections for humans?
- What can veterinarians do to help tackle AMR?
- Which programmes/projects have been developed to produce new antibiotics?
- What is the global economic burden of AMR, per annum?
- Why are there so few new antibiotics being produced?
- How can proper economic investment in Research & Development help tackle AMR?
- Could implementation of taxes for antibiotic use in human and animal health be one of the solutions to this major global health problem?
- If AMR has already been an emerging issue for a long time, why are governments taking so long to act?
- Until now, which reports have been published calling for action on AMR?
- What are the main conclusions in the report on AMR headed by economist Lord Jim O’Neill and commissioned by former UK Prime Minister David Cameron?
- Why is it said that AMR is a “global and multisectoral issue”?
- Which countries have AMR on the top of their political agenda?
- Where can I get more information about AMR in my own country?
- What can policy makers do to help tackle AMR?
- How do we overcome the problem of AMR at the hospital level?
- How can the transfer of resistant microorganisms occur from one patient to another?
- How can doctors help reduce antimicrobial resistance?
- What is the role of pharmaceutical companies in propagating AMR?
- What is the role of pharmacists in the fight against antimicrobial resistance?
- What is the role of nurses in reducing antimicrobial resistance at the hospital level?
Resources
- Denmark Raises Antibiotic-Free Pigs. Why Can’t the U.S. - The New York Times
- The Ganges Brims With Dangerous Bacteria - The New York Times
- National Antibiotic Resistance Policy and Implementation in Spain
- Crisis Looms in Antibiotics as Drug Makers Go Bankrupt
- Stemming the Superbug Tide: Policy Brief 2018 (OECD)
- Vaccination requirements and recommendations for international travelers
- When The Drugs Don't Work - Antibiotic Resistance as a Global Development Problem, February 2019
- Animation of Antimicrobial Resistance (video) (FDA)
- Conserved collateral antibiotic susceptibility networks in diverse clinical strains of Escherichia coli
- Killerkeime - Documentary (German)
- AMR Control Program in Indonesia - Video
- When Antibiotics Fail: Canada 2019
- Sales of veterinary antimicrobial agents in 30 European countries in 2016
- Reframing Resistance: Wellcome Trust Report
- Pharmaceutical Residues in Freshwater: Hazards and Policy Responses
- HCWH Antimicrobial Resistance Press Kit
- Active Immunity by Passive Immunity
- Estimating the Disease Burden of MRSA in Japan
- Outbreak of carbapenemase-producing (NDM-1 and OXA-48) and colistin-resistant Klebsiella pneumoniae ST307, north-east Germany, 2019
- How Does Antibiotic Resistance Spread
- Addressing antimicrobial resistance: progress in the animal sector, but this health threat remains a challenge for the EU
- Japan 2018: Current Status of Anti-Microbial Bacteria in Japan
- Study on AMR in China Using SARS as a Reference
- IMMUNO-VIP and IMMUNO-CIPa) as support in fighting against Superbug Methicillin-Resistant Staphylococcus aureus [MRSA]
- Treatment of UTIs with Antibiotic Resistant Bacteria and Superbugs
- Contribution of biologically active products, Immuno-VIP and Immuno-CIP in the support and amelioration of psoriasis vulgaris symptoms
- Supportive Customized Solution As An Effort in Settling the Antibiotic Resistant Bacterial Infections, Using Immuno-CIP and Immuno-VIP
- Antibiotics are Contaminating the World's Rivers
- Antibiotic Resistance in Plant Pathogenic Bacteria
- AMR: Tackling the Burden In the EU
- AMR Review Update 2019
- Access Barriers to Antibiotics
- Open Letter to MEPs on AMR
- Global Trends in AMR in Animals in Middle and Low Income Countries
- Opinion Article on AMR by Dr Widjaja Lukito
- Reducing Antimicrobial Use in Food Animals
Target Groups
- Tourist and Business Traveler
- AMR Patients and Family
- General public
- Human health professionals
- Animal health professionals
- Farmers
- Politicians and policy makers
- Financial & economic experts
- Industry
Forums
Topics
- For best Man
- Find Out The Particulars Of Search Engine Optimisation
- Is this a real issue in 2020?
- Canada and USA
- Hello. And Bye.1
- Generic now
- Stayhome Now
- Hi! All 4962 Users
- yahoo health care
- How has AMR made nursing more difficult?
FAQ Categories
- General
- Human health professionals
- Farmers
- Animal health professionals
- Politicians and Policy Makers
- Economics and finance experts
- Industry
- AMR Patients and Family of Victims
